<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05085574</url>
  </required_header>
  <id_info>
    <org_study_id>LDOS-21-001-01</org_study_id>
    <nct_id>NCT05085574</nct_id>
  </id_info>
  <brief_title>Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1)</brief_title>
  <official_title>A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of the Combination of Famotidine and Celecoxib as a Treatment in Moderate-to-severe Patients Hospitalized for COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leidos Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Leidos Life Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to test the efficacy and safety of combinations of two well-understood&#xD;
      agents - famotidine and celecoxib in patients hospitalized with moderate-to-severe COVID-19&#xD;
      (based on World Health Organization [WHO] Ordinal Scale for Clinical Improvement). Both&#xD;
      famotidine and celecoxib separately demonstrate clinical activity in mitigating COVID-19&#xD;
      disease symptoms or severity, and appear to have separate and complementary mechanisms of&#xD;
      action.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be randomly assigned, in a 1:1 ratio, to one of two regimens, with 202&#xD;
      subjects per group as follows:&#xD;
&#xD;
      Group 1 (study product) subjects will receive 80 mg famotidine by mouth (PO) twice per day&#xD;
      (QID) + 400 mg celecoxib as a first dose, followed by 200 mg celecoxib PO, 4 times per day&#xD;
      (BID), for 5 days. Following this 5-day period, subjects will continue their famotidine&#xD;
      treatment for an additional 9 days.&#xD;
&#xD;
      Group 2 (reference therapy) subjects will receive matching placebos QID and BID, for 5 days.&#xD;
      Following this 5-day period, subjects will continue to receive matching famotidine placebo,&#xD;
      QID, for an additional 9 days.&#xD;
&#xD;
      Safety, efficacy and pharmacokinetics of famotidine and celecoxib will be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects randomized 1:1, study drug:placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time-to-event to achieve WHO level ≤3</measure>
    <time_frame>30 days</time_frame>
    <description>Evaluation of the time-to-event to achieve a WHO level score ≤3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death rate</measure>
    <time_frame>30 days</time_frame>
    <description>Evaluation of the time-to-event where death occurs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital discharge to chronic palliative care</measure>
    <time_frame>30 days</time_frame>
    <description>Measured incidence of hospital discharge to chronic palliative care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital discharge with no additional medical care</measure>
    <time_frame>30 days</time_frame>
    <description>Measured incidence of hospital discharge with no additional medical care required</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Related adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>90 days</time_frame>
    <description>Measured incidence of related AEs and SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study discontinuation due to related AEs or SAEs</measure>
    <time_frame>90 days</time_frame>
    <description>Measured incidence of study discontinuation due to related AEs or SAEs</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacokinetic (PK) endpoint-Assess area under the curve</measure>
    <time_frame>14 days</time_frame>
    <description>Measure area under the curve (AUC) for famotidine and celecoxib combination in 10 patients per group</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic (PK) endpoint-Assess time to maximum plasma concentration</measure>
    <time_frame>14 days</time_frame>
    <description>Measure time to maximum plasma concentration (tmax) for famotidine and celecoxib combination in 10 patients per group</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic (PK) endpoint-Assess maximum serum concentration</measure>
    <time_frame>14 days</time_frame>
    <description>Measure maximum serum concentration (Cmax) for famotidine and celecoxib combination in 10 patients per group</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory endpoint-Incidence of symptom reduction</measure>
    <time_frame>14 days</time_frame>
    <description>Cumulative incidence of clinically significant symptom reduction (severity and duration) using COVID-19 Symptom Score</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory endpoint-Incidence of clinical improvement</measure>
    <time_frame>14 days</time_frame>
    <description>Cumulative incidence of clinically significant symptom reduction (severity and duration) using WHO Ordinal Scale for Clinical Improvement</description>
  </other_outcome>
  <other_outcome>
    <measure>Special Assessment - High-resolution computed tomography (HRCT), 20 patients/group, change from baseline</measure>
    <time_frame>Study Day 1 (baseline), Day 16 (discharge), 30 days after first dose, and 90 days after first dose</time_frame>
    <description>HRCT scan of the chest</description>
  </other_outcome>
  <other_outcome>
    <measure>Special Assessment - Total lung capacity (TLC), 20 patients/group, change from baseline</measure>
    <time_frame>Study Day 1 (baseline), 16 (discharge), 30 days after first dose, and 90 days after first dose</time_frame>
    <description>TLC</description>
  </other_outcome>
  <other_outcome>
    <measure>Special Assessment - Prostaglandin E2 (PGE2), 20 patients/group, change from baseline</measure>
    <time_frame>Study Day 1 (baseline), 16 (discharge), 30 days after first dose, and 90 days after first dose</time_frame>
    <description>PGE2 testing</description>
  </other_outcome>
  <other_outcome>
    <measure>Special Assessments - Urinalysis, 20 patients/group, change from baseline</measure>
    <time_frame>Study Day 1 (baseline) and 16 (discharge)</time_frame>
    <description>Urinalysis</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">404</enrollment>
  <condition>2019 Novel Coronavirus Disease</condition>
  <condition>2019 Novel Coronavirus Infection</condition>
  <condition>2019-nCoV Disease</condition>
  <condition>2019-nCoV Infection</condition>
  <condition>COVID-19 Pandemic</condition>
  <condition>COVID-19 Virus Disease</condition>
  <condition>COVID-19 Virus Infection</condition>
  <condition>Covid19</condition>
  <condition>Coronavirus Disease 2019</condition>
  <condition>SARS-CoV-2 Infection</condition>
  <condition>SARS-CoV-2 Acute Respiratory Disease</condition>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Group 1 (Study Product)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 80 mg famotidine (PO) QID and 400 mg celecoxib as a first dose, followed by 200 mg (PO) BID celecoxib, for 5 days. Following this 5-day period, subjects will continue their famotidine treatment for an additional 9 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (Reference Therapy)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive matching placebos QID and BID, for 5 days. Following this 5-day period, subjects will continue to receive matching famotidine placebo, QID, for an additional 9 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famotidine</intervention_name>
    <description>80 mg tablet, QID for 14 days</description>
    <arm_group_label>Group 1 (Study Product)</arm_group_label>
    <other_name>Pepcid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>400 mg (initial dose), then 200 mg capsule, BID for 5 days</description>
    <arm_group_label>Group 1 (Study Product)</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tablet, QID for 14 days; capsule, BID for 5 days</description>
    <arm_group_label>Group 2 (Reference Therapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female participants must be at least 18 years of age, inclusive, at the time&#xD;
             of signing the informed consent form.&#xD;
&#xD;
          -  Confirmed COVID-19 or symptom onset within 7 days of hospitalization, as shown by&#xD;
             medical history, physical exam, and laboratory tests (PCR), and who have been&#xD;
             hospitalized for COVID-19 at WHO Grade 4-5.&#xD;
&#xD;
          -  Contraceptive use by men or women should be consistent with Appendix 4 of the Master&#xD;
             Protocol (LDOS-21-001).&#xD;
&#xD;
          -  Capable of understanding and providing signed informed consent.&#xD;
&#xD;
          -  Reliable access to the internet.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants are excluded from the study if any of the following criteria apply:&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  History of HIV&#xD;
&#xD;
          -  Ongoing treatment that cannot be temporarily discontinued during the study:&#xD;
             anti-inflammatory treatment (nonsteroidal anti-inflammatory drugs&#xD;
             [NSAIDS]);corticosteroids; antimalarials; antiarrhythmics; tricyclic antidepressants;&#xD;
             natalizumab; quinolones; macrolides; and agalsidase alfa and beta&#xD;
&#xD;
               1. drugs dependent on gastric pH for absorption, e.g., dasatinib, delavirdine,&#xD;
                  mesylate, cefditoren, and fosamprenavir;&#xD;
&#xD;
               2. tizanidine (CYP1A2) substrate;&#xD;
&#xD;
               3. drugs that interfere with hemostasis (e.g., warfarin, aspirin, selective&#xD;
                  serotonin reuptake inhibitors [SSRIs]/serotonin norepinephrine reuptake&#xD;
                  inhibitors [SNRIs]);&#xD;
&#xD;
               4. angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers&#xD;
                  (ARB), or beta-blockers;&#xD;
&#xD;
               5. diuretics;&#xD;
&#xD;
               6. digoxin&#xD;
&#xD;
          -  Ongoing famotidine, celecoxib, or other COVID-19 clinical investigational treatment(s)&#xD;
             within the past 30 days or current participation in another investigational clinical&#xD;
             trial&#xD;
&#xD;
          -  History of immunosuppression&#xD;
&#xD;
          -  History of asthma, urticaria, or other allergic-type reactions after taking aspirin or&#xD;
             other NSAIDs&#xD;
&#xD;
          -  Rejection of participation at the discretion of the Principal Investigator or Sponsor&#xD;
&#xD;
          -  Any contraindication for famotidine or celecoxib treatment:&#xD;
&#xD;
             a. Famotidine or celecoxib hypersensitivity; b. Retinopathy, visual field or visual&#xD;
             acuity disturbances; c. History of cardiovascular disease, such as congestive heart&#xD;
             failure, QT prolongation, bradycardia (&lt;50 bpm), ventricular tachycardia, other&#xD;
             arrhythmias, as determined at screening electrocardiogram (ECG) or medical history; d.&#xD;
             Potassium &lt;3 mEq/L (milliequivalent/liter) as determined at Visit 1; e. Aspartate&#xD;
             aminotransferase (AST) or alanine aminotransferase (ALT) &gt;5 upper normal limit, as&#xD;
             determined at Visit 1; f. Previous myocardial infarction; e. Myasthenia gravis; h.&#xD;
             Psoriasis or porphyria; i. Glomerular clearance, 60 mL/min; j. Previous history of&#xD;
             severe hypoglycemia; k. Known or suspected to be poor CYP2C9 metabolizers based on&#xD;
             genotype or previous history or experience with other CYP2C9 substrates, such as&#xD;
             warfarin and phenytoin; l. Moderate or severe hepatic impairment, e.g., Child-Pugh&#xD;
             Class B or C.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian A Roberts, MS, PMP</last_name>
    <role>Study Director</role>
    <affiliation>Leidos, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brian A Roberts, MS, PMP</last_name>
    <phone>240-529-0455</phone>
    <email>brian.a.roberts@leidos.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tilly Lawrence, BSN, RN</last_name>
    <phone>240-529-0497</phone>
    <email>tilly.lawrence@leidos.com</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 7, 2021</study_first_submitted>
  <study_first_submitted_qc>October 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>COVID</keyword>
  <keyword>COVID19</keyword>
  <keyword>SARS-CoV-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Famotidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>It is not yet known if there will be a plan to make individual participant data (IPD) available.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

